Comment on news

By adminAugust 18, 2021Global News Feed

On 16 August 2021 in an article in newspaper Diena J?nis Buks, chairperson of JSC Olainfarm, provided an opinion on future listing of JSC Olainfarm shares on the stock exchange where it is mentioned that some shareholders are contemplating about delisting of JSC Olainfarm shares from the regulated market. With this we would like to inform that only shareholders meeting can make a decision to delist shares from the stock exchange. At the moment a shareholders meeting where such proposal would be reviewed has not been called.

Follow this link:
Comment on news

Better Choice Company Board of Directors Authorize Stock Repurchase Program

By adminAugust 18, 2021Global News Feed

NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE American: BTTR) (“Better Choice” or “the Company”), an animal health and wellness company, today announced that its Board of Directors has authorized a stock repurchase program under which the Company can repurchase up to $2 million of the currently outstanding shares of the Company’s common stock, until December 31, 2021.

The rest is here:
Better Choice Company Board of Directors Authorize Stock Repurchase Program

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine…

By adminAugust 18, 2021Global News Feed

A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition

See the original post:
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine...

22nd Century to Present at SNN Network Investor Conference on August 19

By adminAugust 18, 2021Global News Feed

BUFFALO, N.Y., Aug. 17, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced that its Chief Executive Officer, James A. Mish, is scheduled to present at the SNN Network Summer Virtual Event investor conference on Thursday, August 19, 2021 at 2:30 p.m. ET.

Read the rest here:
22nd Century to Present at SNN Network Investor Conference on August 19

Greenrose Acquisition Corp. Increases Full Year 2022 Financial Outlook

By adminAugust 18, 2021Global News Feed

- Increased 2022 Financial Projections Reflect Theraplant’s Upside Potential from Projected 2022 Commencement of Recreational Marijuana Sales in Connecticut -

Visit link:
Greenrose Acquisition Corp. Increases Full Year 2022 Financial Outlook

XcelPlus International inks letter of intent to build plasma gasifiers for India landfill removal consortium

By adminAugust 18, 2021Global News Feed

RENO, NV, Aug. 17, 2021 (GLOBE NEWSWIRE) -- XcelPlus International Inc. (OTC PINK: XLPID) announced today that it has received a signed letter of intent to build plasma gasifiers for a landfill removal consortium based in India.

Here is the original post:
XcelPlus International inks letter of intent to build plasma gasifiers for India landfill removal consortium

Cosmos Holdings Reports 15.8% Year-Over-Year Growth and 27.8% Sequential Increase in Revenue for the Second Quarter of 2021

By adminAugust 18, 2021Global News Feed

CHICAGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the second quarter ended June 30, 2021.

Read the original:
Cosmos Holdings Reports 15.8% Year-Over-Year Growth and 27.8% Sequential Increase in Revenue for the Second Quarter of 2021

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and…

By adminAugust 18, 2021Global News Feed

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical progress update for the second quarter 2021.

See the original post here:
Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and...

Accelus Launches Ultra-Low-Profile FlareHawk7™ Expandable Cage Implant and Innovative Instruments to Support Endoscopic, MIS Lumbar Fusion…

By adminAugust 18, 2021Global News Feed

New 7mm insertion profile, combined with company’s proprietary Adaptive Geometry™ technology, are designed to respect patients’ neural, vascular, bony and soft tissue anatomy both during and after insertion to promote long-term stability New 7mm insertion profile, combined with company’s proprietary Adaptive Geometry™ technology, are designed to respect patients’ neural, vascular, bony and soft tissue anatomy both during and after insertion to promote long-term stability

See the original post here:
Accelus Launches Ultra-Low-Profile FlareHawk7™ Expandable Cage Implant and Innovative Instruments to Support Endoscopic, MIS Lumbar Fusion...

Zivo Bioscience, Inc. Issues Letter to Shareholders

By adminAugust 18, 2021Global News Feed

KEEGO HARBOR, Mich., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today issues a letter to shareholders from Chief Executive Officer Andrew Dahl.

Continued here:
Zivo Bioscience, Inc. Issues Letter to Shareholders